Ozempic vs Wegovy: What's the Difference? (2026 Guide)

The most important difference between Ozempic and Wegovy is their FDA-approved indication. Ozempic is approved to improve blood sugar control in adults with type 2 diabetes and to reduce cardiovascular risk. Wegovy is approved for chronic weight management in adults with obesity or overweight with a weight-related condition.

Both use the same active ingredient (semaglutide) at similar weekly injection schedules, but the approved dose ranges differ. Wegovy's maximum approved dose (2.4mg/week) is higher than Ozempic's (2.0mg/week).

This matters because doctors can only prescribe each medication for its approved indication—or off-label, which affects insurance coverage.

Ozempic is available in doses of 0.5mg, 1.0mg, and 2.0mg per week. It uses a titration schedule that starts at a lower dose and increases over time.

Wegovy is available in doses of 0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg per week, with a longer titration schedule intended to maximize tolerability.

The higher maximum dose of Wegovy is one reason clinical trials showed greater average weight loss with Wegovy than with lower doses of Ozempic used off-label for weight loss.

For patients with type 2 diabetes, Ozempic has a longer track record of insurance coverage and is more commonly found on commercial formularies.

Wegovy coverage for weight loss has historically been harder to get, though coverage has expanded in 2025–2026 as more insurers recognize obesity treatment as medically necessary.

Medicare Part D now covers Wegovy for obesity under plans that include anti-obesity medications—this is a significant change from prior years, where Medicare excluded most weight loss drugs.

The practical implication: if you have type 2 diabetes, Ozempic may be easier to get covered. If you're seeking treatment primarily for weight, Wegovy may now be your better insurance bet depending on your plan.

Ozempic is widely prescribed off-label for weight loss in patients who don't have type 2 diabetes. This became extremely common during the period when Wegovy was in shortage, and it has continued.

Off-label prescriptions are legal and common in medicine, but insurance typically won't cover Ozempic when prescribed for weight loss only—leaving patients to pay the full retail price.

Wegovy prescribed for obesity, by contrast, is on-label and increasingly covered under anti-obesity medication benefits.

Both medications have similar list prices without insurance—typically $900–$1,300 per month depending on the dose. Neither is dramatically cheaper than the other at retail.

The meaningful cost difference appears when you factor in insurance. If your plan covers Wegovy for obesity, your out-of-pocket cost may be a copay rather than the full price. If you're using Ozempic off-label for weight loss, you're likely paying out of pocket.

For patients without coverage, both lead back to the same alternative: compounded semaglutide, available for $150–$400/month through telehealth providers.

If you have type 2 diabetes, Ozempic is typically the first conversation to have with your doctor—it has a longer approval history for this indication.

If you're seeking treatment primarily for weight management, Wegovy is the on-label choice and gives you the best chance of insurance coverage under plans that include obesity benefits.

For those paying out of pocket, the brand-name choice matters less. Compounded semaglutide programs don't distinguish between the two—they provide the same active ingredient at a much lower cost.